Related Experiment Video
Updated: Feb 12, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Experience with eribulin in triple-negative metastatic breast cancer: case studies
Maria Isabel Gallegos Sancho1, Raúl Márquez-Vázquez2, Alfonso Sánchez-Muñoz3
1Medical Oncology Department, Complejo Asistencial De Segovia, Segovia, Spain.
Abstract:
Triple-negative breast cancers are defined as tumors negative for estrogen receptors, progesterone receptors and human EGFR2. These tumors exhibit diverse biological behavior and have a poor prognosis; chemotherapy is the mainstay of treatment. The first case involves a young woman with cerebral and cerebellar metastases who achieved a persistent objective response to fourth-line eribulin. In the second case, a woman who became metastatic during adjuvant therapy with anthracyclines and taxanes, and was refractory to capecitabine + bevacizumab, achieved a partial response and local symptom improvement with eribulin + bevacizumab. Last, a poly-treated patient demonstrated reasonable response and longer progression-free interval on third-line eribulin relative to previous lines of chemotherapy which is unusual in this clinical setting.
Insights
Eribulin shows promise in treating advanced triple-negative breast cancer (TNBC) that has spread to the brain. This chemotherapy offers a valuable option for patients with limited treatment alternatives.
Area of Science:
- Oncology
- Medical research
Background:
- Triple-negative breast cancer (TNBC) lacks targeted therapies and has a poor prognosis.
- Chemotherapy remains the primary treatment for TNBC.
- Metastatic TNBC, especially with brain involvement, presents significant treatment challenges.
Observation:
- Three distinct cases of patients with advanced TNBC are presented.
- Case 1: Young woman with cerebral/cerebellar metastases responded to fourth-line eribulin.
- Case 2: Metastatic patient refractory to capecitabine + bevacizumab achieved partial response with eribulin + bevacizumab.
- Case 3: Heavily pre-treated patient showed improved progression-free interval with third-line eribulin.
Findings:
- Eribulin demonstrated efficacy in heavily pre-treated and metastatic TNBC patients.
- Objective responses and improved progression-free intervals were observed.
- Combination therapy with bevacizumab showed potential benefit.
Implications:
- Eribulin may be a viable treatment option for refractory or advanced TNBC.
- Further investigation into eribulin's role in TNBC, including brain metastases, is warranted.
- These findings support exploring novel therapeutic strategies for poor-prognosis breast cancer subtypes.
More Related Videos
09:44Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior
Published on: June 13, 2016
05:05Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy
Published on: November 29, 2018
Related Concept Videos
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
Negative Regulator Molecules
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Positive, Negative, and Zero Work
What is an Experiment?
The Stanford Prison Experiment